On November 12, 2024, Novo Nordisk A/S reported the purchase of 1,300 ADRs at DKK 743.31 each by board member Christina Law, totaling DKK 966,301.02. This filing classifies under 'Changes in management or control' as it discloses trading activities by company executives, and it is significant due to the involvement of board members.